Oleg Nodelman bought $13.1M of Zymeworks (ZYME)
Executed Mar 11 2025, disclosed Mar 13 2025, 2 days later.
Over the 21 trading sessions from the disclosed entry session (Mar 13 2025), the stock returned -23.1% (delay-adjusted); from the execution session (Mar 11 2025), -11.6%. Derived: entry at the session's open, exit at the close 20 sessions later.
Oleg Nodelman (Director) filed 2 Form 4 reports in the past 24 months (2 purchases, 0 sales), most often in Zymeworks Inc. (ZYME). Across 2 priced purchase filings, the average 21-session return was +0.2% from execution and -3.7% from disclosure (delay-adjusted; derived). The largest single filing was $13.1M of ZYME (1,081,980 sh across 3 lots, as filed), executed Mar 11 2025.
Healthcare · Zymeworks Inc., a biotechnology company, develops biotherapeutics for the treatment of cancer, inflammation, and autoimmune diseases
More Healthcare filings→ Insider filings, newest first→ View the original filing at www.sec.gov→317,208 sh across 2 lots
Exec Apr 3 2025
Filed Apr 7 2025 · 5:30 PM ET